In particular, CD19-targeted car-modified T cell therapy (CAR-T) for refractive ALL achieved remission rates of 70–93% [28], clearly indicating the value of CD19 as an important therapeutic target against lymphocytic malignancies. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.